Skip to main content
Back
Watch Compare

Lexaria Bioscience Corp.

Data quality: 100%
LEXX
Nasdaq Manufacturing Chemicals
$0.94
▼ $0.01 (-1.12%)
Mkt Cap: 23.51 M
Price
$0.94
Mkt Cap
23.51 M
Day Range
$0.94 — $0.99
52-Week Range
$0.46 — $1.69
Volume
60,818
Open $0.97
50D / 200D Avg
$0.74
28.19% above
50D / 200D Avg
$0.89
6.67% above

Quick Summary

Key Takeaways

Revenue declined -0.59% annually over 5 years
Negative free cash flow of -8.71 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 52.64%
Capital efficient — spends only 0.00% of revenue on capex

Growth

Revenue Growth (5Y)
-0.59%
Below sector avg (1.82%)
Revenue (1Y)52.05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-206.27%
Below sector avg (-53.41%)
ROIC-172.70%
Net Margin-2067.65%
Op. Margin-2062.00%

Safety

Debt / Equity
N/A
Current Ratio3.68
Interest CoverageN/A

Valuation

PE (TTM)
-2.18
Below sector avg (-1.48)
P/B Ratio4.78
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.2 -1.5
P/B 4.8 1.6
ROE % -206.3 -53.4
Net Margin % -2067.7 -41.5
Rev Growth 5Y % -0.6 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 52.05% Revenue Growth (3Y) 76.65%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0.59% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 522,000.0 Net Income (TTM) -10.79 M
ROE -206.27% ROA -168.75%
Gross Margin 100.00% Operating Margin -2062.00%
Net Margin -2067.65% Free Cash Flow (TTM) -8.71 M
ROIC -172.70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.68
Interest Coverage N/A Asset Turnover 0.08
Working Capital 3.91 M Tangible Book Value 4.60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.18 Forward P/E N/A
P/B Ratio 4.78 P/S Ratio 45.03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -37.05%
Market Cap 23.51 M Enterprise Value 19.21 M
Per Share
EPS (Diluted TTM) -0.57 Revenue / Share 0.02
FCF / Share -0.35 OCF / Share -0.35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion 80.68%
SBC-Adj. FCF -9.52 M Growth Momentum 52.64

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 705,923.0 464,278.0 226,208.0 255,397.0 722,738.0
Net Income -11.90 M -5.80 M -6.66 M -7.27 M -4.19 M
EPS (Diluted) -0.66 -0.47 — — —
Gross Profit 703,203.0 459,456.0 194,708.0 183,556.0 547,392.0
Operating Income -11.88 M -5.75 M -6.53 M -7.38 M —
EBITDA — — — — —
R&D Expenses 8.24 M 2.36 M 3.67 M 1.84 M 1.26 M
SG&A Expenses — — — — —
D&A 51,225.0 76,153.0 145,397.0 102,718.0 —
Interest Expense — 7,760.0 — — —
Income Tax — — — 0.0 6,093.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4.18 M 8.87 M 3.08 M 7.83 M 13.27 M
Total Liabilities 1.57 M 1.21 M 403,908.0 201,437.0 203,265.0
Shareholders' Equity 2.99 M 8.04 M 3.04 M 7.95 M 13.06 M
Total Debt — — — — —
Cash & Equivalents — — — 5.81 M 10.92 M
Current Assets 3.47 M 7.90 M 2.20 M 6.98 M 12.44 M
Current Liabilities 1.49 M 1.10 M 267,735.0 194,036.0 153,276.0